TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Polyunsaturated Fatty Acids in Children and Adolescents With Attention Deficit/ Hyperactivity Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written Informed Consent by parents and patients (separately for age groups 6 - 11 years and 12 - 17 years)~* Children and adolescents of both gender in the age group between 6 and 17 years~* Confirmed diagnosis of ADHD by semi-structured clinical interview Kiddie Schedule for Affective Disorders and Schizophrenia for school-age children (K-SADS)~* ADHDRS-IV-Parent Version (18-Item-Scale): Investigator Administered and Scored ≥24~* Sufficient knowledge of the German language~Exclusion Criteria:~* Known hypersensitivity against components of either the verum or placebo food~* All serious internal diseases~* All severe psychiatric diseases except oppositional defiant disorders~* Current intake of the following medication: antidepressants and other psychotropic medication~* Recent intake of ω-3 fatty acids supplementation~* Indication for hospitalization~* Suicidality (including suicidal thoughts)~* intelligence quotient \< 70~* Previous medication with stimulants within 4 weeks~* Placement in an institution on official or judicial ruling~* Lack of willingness to store and transmit pseudonym data according to German regulations~* Parallel participation in another trial, or less than 4 weeks ago~* Patients foreseeable requiring a primary medication with methylphenidate during the study period of 12 weeks

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- ω-3 fatty acids suspension (Type: ACTIVE_COMPARATOR): 2 bags of Esprico(R) suspension each day. Each 4ml suspension bag includes 400mg eicosapentaenoic acid (EPA), 40mg docosahexaenoic acid (DHA), 5.4 mg gamma-linolenic acid (GLA), 80 mg magnesium, 5 mg zinc and consists of linseed oil, xylitol, sea fish oil with high portion of omega-3-acids, magnesium citrate, vegetable oil, orange flavour, evening primrose oil, zink gluconate, soya lecithin, citric acid, acesulfame k (E950)
- placebo suspension (Type: PLACEBO_COMPARATOR): 2 bags of Esprico (R) placebo suspension. Includes no ω-3 fatty acids, no ω-6 fatty acids, no magnesium and no zinc, but other vegetable oils, orange flavor, etc.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Caucasian postmenopausal women~* BMI 30-38~Exclusion Criteria:~* Not currently weight-stable~* Diagnosed with diabetes~* Cardiovascular disease~* Endocrine disease~* Hepatic and renal disorders~* Neurological/psychological illness/history of depression~* Previous surgical procedures for weight loss~* Medications known to alter body weight or appetite~* β-blockers, fibrates and metformin~* Severe under-reporting of food intake based on a 4 day food diary

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Rimonabant treatment (20mg/d) for 12 weeks
- 2 (Type: OTHER): Dietary intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Cosmetic Outcome at 4 Months in Hand and Feet Lacerations in Children: Conservative Versus Suture Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any English-speaking child, 2 to 17 years of age that presents to the emergency department at Cardinal Glennon Children's Medical Center with a hand or foot laceration less than or equal to 2 cm is eligible for the study.~Exclusion Criteria:~* Patients will be excluded if their laceration is greater than 2 cm, have irregular borders or are, deeper than 0.5 cm.~* Wounds that are the result of a mammalian bite,~* Wounds more than minimally contaminated on visual inspection or are more than 8 hours old.~* Wounds associated with an open fracture, involve a partial amputation or involve a puncture wound.~* Wounds that involve the nailbed or a fingernail avulsion will be excluded.~* Patients with confirmed or suspected retained foreign bodies in the wound would also be excluded.~* Patients will also be excluded if hemostasis could not be attained after 15 minutes of pressure.~* Patients with complex lacerations who need plastic surgery or other sub-specialty repair will be excluded.~* Complex lacerations include: associated or suspected neurovascular, tendon, ligament, or bone injury, need for deep/multi-layer sutures will be excluded.~* Patients with known or suspected immunodeficiency, bleeding or clotting disorders, pregnancy, diabetes, renal dysfunction, or allergic reaction to local anesthesia are also excluded.~* Patients with a history of anticoagulant or chronic steroid use in the last year. Chronic steroid use is defined by use of steroids (PO, IV, IM, or topical) for more than 14 consecutive days, for more than 3 separate courses per year will be excluded.~* Foster children will also be excluded, due to complications regarding custody, consent, and follow-up issues.~* Patients with allergies to topical anesthetics solution will be excluded from the study.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- conservative (Type: NO_INTERVENTION): patient fulfilling entry criteria will be randomized to the conservative arm - no suturing
- suture (Type: ACTIVE_COMPARATOR): patient fulfilling entry criteria will be randomized to the suture arm for repair with nylon suture material

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Esmolol for Treatment of Perioperative Tachycardia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or Females~2. Age \> 40y/o~3. Scheduled high risk (ASA II-IV) non-cardiac surgery with anticipated 12 hour post-operative ICU care~4. Written informed consent~5. Patients on a stable chronic oral beta-blocker therapy~6. Revised Cardiac Risk Index 1(below) Cardiac Risk Index 1 or greater (below)~   * a history of coronary disease~  * a history of congestive heart failure~  * a history of treated diabetes~  * a history of cerebrovascular disease~  * a history of chronic renal failure~Exclusion Criteria:~1. Active bleeding~2. Untreated left main disease~3. Active cardiac condition (eg unstable angina pectoris, acute exacerbation of CHF, serious arrhythmias, symptomatic valve disease)~4. Preoperative positive troponin T~5. Contraindication for esmolol use~6. Previous allergy or intolerance to esmolol~7. Cancer with an expected life expectancy \< 6 months~8. Pregnancy or lactating or planning to become pregnant~9. Failure to provide informed consent, unable to understand or follow instructions.~10. History of drug allergy or idiosyncrasy to beta-adrenergic drugs~11. Recent history (within 1 year) of drug or alcohol abuse~12. Patients with a Pacemaker~13. Abnormal liver function Child-Pugh - B~14. Body Mass Index \> 45~15. Reactive airway disease (defined as a history of hospitalization with status asthmaticus within the past one year)~16. Surgery scheduled to begin after 2pm

- Gender: ALL
- Minimum Age: 41 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- oral long acting beta blocker (Type: ACTIVE_COMPARATOR): oral administration of long acting beta blocker as standard of care on the day of surgery
- Esmolol infusion (Type: EXPERIMENTAL): given 30 minutes prior to induction up to 12 hours post-op

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: AKI in Thoracic and Abdominal Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 21 (per manufacturer's instructions on the Nephrocheck kit)~* history of hypertension, whether medically treated or untreated~* scheduled for Anesthesia preoperative clinic visit~* scheduled to undergo prolonged intra-abdominal or intra-thoracic surgeries (defined as scheduled intraoperative time ≥ 4h). Intra-abdominal surgeries will include colorectal surgery, massive ventral hernia repairs, hepatobiliary surgery and gynecologic-oncology surgery. Intra-thoracic surgeries will include video-assisted thoracoscopic surgery (VATS)-assisted segmentectomy and lobectomies, as well as mediastinal mass excisions.~* will be anticipated to be admitted to the ICU for a minimum of 2-3 days post-operatively~Exclusion Criteria:~* history of chronic kidney as defined by estimated glomerular filtration rate (GFR) \<90~* patient taking NSAIDs on a daily basis~* patients with a reported allergy or intolerance to NSAIDs

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketorolac (Type: None): Patients who receive ketorolac perioperatively
- Caldolor (Type: None): Patients who receive Caldolor perioperatively
- No NSAIDS (Type: None): Patients who do not receive NSAIDS perioperatively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CALLSAS Study: Effect of Continuous Positive Airway Pressure Treatment for Obstructive Apnea on Phone Usage Habits

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed OSA patients initiated on CPAP~* Follow-up at home by AGIR à dom~* Customers of Orange (or Sosh) for mobile and/or fixed-line telephony for at least 6 months~* Patient who signed a written consent to participate in the study~* Patient affiliated to social security~Exclusion Criteria:~* Pregnant women~* Patients with disease not allowing to realize functional and locomotion tests~* Person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure (patient under guardianship or curatorship)~* Patient who, in the judgment of the investigator, may not be cooperative or respectful of the obligations inherent to participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CPAP treatment (Type: OTHER): All included OSA patients are going to be treated by CPAP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven Exocrine Adenocarcinoma of the pancreas~* Clinically resectable or marginally resectable disease~* No prior radiation or chemotherapy for carcinoma of the pancreas~* ECOG performance status of 0-1~* Patients must be medically able to undergo surgical resection~* Patients of child bearing potential must follow study specific precautions~* Women that are lactating will not be excluded on the condition that they dispose their breast milk.~* Adequate hematologic and biochemical parameters.~Exclusion Criteria:~* Prior treatment for pancreatic cancer.~* Concurrent investigational treatments.~* Unresectable pancreatic mass.~* Neuroendocrine Histological pancreatic cancer~* Distant Metastatic disease~* Any condition that, in the option of the investigator, would compromise the well being of the patient or anything that would prevent the patient from meeting or performing study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Resectable Patients (Type: EXPERIMENTAL): Surgery with Intraoperative Radiation Therapy (IORT). Radiation Therapy within 6-8 weeks after surgery followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery
- Marginally Resectable Patients (Type: EXPERIMENTAL): 2-3 cycles of neoadjuvant FOLFIRINOX then restaged, then undergo surgery with Intraoperative Radiation Therapy (IORT) within 2-4 weeks following chemotherapy. Then Radiation Therapy within 6-8 weeks followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery for a total of 2-4 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A primary psychiatric diagnosis of Major Depressive Disorder as defined by DSM-IV~* Diagnosis of prostate, colorectal, lung or pancreatic cancer (stage 1-4)~* A score of 16 or above in the 17-item HAM-D (Hamilton depression scale)~* Male or female ages 18-75.~* Ability to give consent~* English and/ or Spanish Speaking~Exclusion Criteria:~* Lifetime history of psychosis or bipolar disorder~* History of substance abuse or dependence in the three months prior to the study.~* Current suicide risk.~* Patients who have ever failed IPT in the context of cancer.~* Patients who are receiving effective medication for depression~* Patients with T3, T4 and THS abnormal values

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Interpersonal Psychotherapy (IPT) (Type: EXPERIMENTAL): Interpersonal psychotherapy (IPT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) in several controlled trials. This study will test the efficacy of IPT in a group of prostate, colorectal, lung and pancreatic cancer patients with a diagnosis of major depressive disorder.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Flourish HEC and BioGenesis to Improve Conception

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Women part of a cisgender couple aged 18 to 40 who are attempting to become pregnant and are attending a fertility clinic.~Exclusion Criteria:~1. Pregnant~2. Lactating~3. Severe male factor, hormonal imbalance (oligoovulatory/anovulatory cycles, cycles longer than 35 days), genetic abnormalities (chromosomal abnormality, common genetic mutation between partners), or severe uterine or tubal factor~4. Any diagnosis that would require the participant to undergo in vitro fertilization to become pregnant~5. Known allergies to any component of BioNourish®, Balance, BiopHresh®, or BioGenesis™~6. Known active vaginal infection at enrollment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Control arm (Type: NO_INTERVENTION): Women follow routine care only, including prescribed medications and recommended techniques and supplements for attempting to become pregnant at home for up to three months.
- Flourish HEC + BioGenesis arm (Type: EXPERIMENTAL): In addition to routine care followed by women in control arm, women in this arm also use the Flourish HEC (Hydroxyethylcellulose) vaginal care system and BioGenesis fertility lubricant for up to three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-guided Biopsy of the Pleura as a Supplement to Extraction of Fluid in Patients With One-sided Fluid in the Pleura

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years.~* Patients with a previous thoracentesis of a unilateral exudative pleural effusion according to Light's criteria (1) without malignant cells.~* CT thorax or PET-CT with contrast performed.~* Clinical suspicion of cancer such as (but not limited to) weight loss or PET-CT results or former cancer diagnosis.~* Patients must be able to give informed consent.~Exclusion Criteria:~* Bilateral pleural effusions.~* Known cause of pleural effusions.~* Life expectancy \<3 months.~* Inability to understand written or spoken Danish.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrasound-guided thoracentesis (Type: ACTIVE_COMPARATOR): Ultrasound guided thoracentesis
- Ultrasound-guided pleural biopsy and thoracentesis (Type: EXPERIMENTAL): Ultrasound-guided biopsy of the parietal pleura is taken through the same incision as the optimal site for thoracentesis and immediately prior to ultrasound-guided thoracentesis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Home Based Exercise Program for Elderly Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Endometrial, Ovarian, Cervix, Vaginal Cancer Initiating Chemotherapy~* Age greater than or equal to 65yrs~* ECOG (Eastern Cooperative Oncology Group) performance status less than 3~* No current physical therapy intervention~* English speaking~Exclusion Criteria:~* Non-gynecologic malignancy~* Recurrent cancer~* Receiving radiation alone~* Gait or balance disturbance

- Gender: FEMALE
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
- Observation (Type: NO_INTERVENTION): Subjects randomized to observation will only have physical therapy assessment using the Berg Balance Test and 6min Walk Test at baseline and end point. These subjects will not receive any exercise teaching.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Stepped-care Model of Tailored Behavioural Medicine Pain Intervention in Primary Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* musculoskeletal pain from the low back, neck or with widespread locations~Exclusion Criteria:~* patients scoring high on the Montgomery Åsberg Depression Rating Scale (MADRS; \> 35 or \> 4 on the suicidal risk item)~* patients suffering from other psychiatric or severe medical co-morbidity (e.g. cancer)~* patients presenting a history and physical symptoms indicating serious spinal pathology (red flags) implying further diagnostic examination or acute measures.~* patients not being able to read, write and discuss their everyday life situation in Swedish or accepting an interpreter are not included~* patients who have completed multimodal treatments due to the current pain condition during the past two years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tailored behavioural medicine (Type: EXPERIMENTAL): After having received a minimal intervention (step 1) comprising 'stay-active advice', participants scoring \>90 on the Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) are randomly allocated to an eight-week treatment in step 2, depending on risk profile. The experimental condition includes supervised physical exercises integrated with either (a) graded activity, or (b) hierarchical graded exposure depending on risk profile, i.e. absence or presence of pain catastrophizing and fear-avoidance beliefs.
- Control group (Type: ACTIVE_COMPARATOR): Participants will be scheduled for supervised, regular Physical exercises twice a week during eight weeks 8. Participants with a moderate to high disability risk profile will receive: Tailored graded activities training.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy